Data Insights

Serplulimab by Shanghai Henlius Biotech for Small-Cell Lung Cancer: Likelihood of Approval

Serplulimab is under clinical development by Shanghai Henlius Biotech and currently in Phase III for Small-Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Serplulimab in Small-Cell Lung Cancer

Data Insights

Rituximab biosimilar by Shanghai Henlius Biotech for Follicular Lymphoma: Likelihood of Approval

Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Follicular Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Rituximab Biosimilar in Follicular Lymphoma

Data Insights

Bevacizumab biosimilar by Shanghai Henlius Biotech for Hepatocellular Carcinoma: Likelihood of Approval

Bevacizumab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Hepatocellular Carcinoma

Data Insights

Rituximab biosimilar by Shanghai Henlius Biotech for Follicular Lymphoma: Likelihood of Approval

Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Follicular Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Rituximab Biosimilar in Follicular Lymphoma

Data Insights

Denosumab biosimilar by Shanghai Henlius Biotech for Post Menopausal Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Pre-Registration for Post Menopausal Osteoporosis. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Post Menopausal Osteoporosis

Data Insights

Serplulimab by Shanghai Henlius Biotech for Esophageal Cancer: Likelihood of Approval

Serplulimab is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Serplulimab in Esophageal Cancer

Data Insights

Denosumab biosimilar by Shanghai Henlius Biotech for Giant Cell Tumor Of Bone: Likelihood of Approval

Denosumab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase I for Giant Cell Tumor Of...

Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Giant Cell Tumor Of Bone

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal...

Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biobetter in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Gastric Cancer: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Gastric Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biobetter in Gastric Cancer

Data Insights

Rituximab biosimilar by Shanghai Henlius Biotech for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Extranodal Marginal Zone B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Rituximab Biosimilar in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Recurrent Head And Neck...

Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biobetter in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Nasopharyngeal Cancer: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Nasopharyngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biobetter in Nasopharyngeal Cancer

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Squamous Non-Small Cell Lung...

Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biobetter in Squamous Non-Small Cell Lung Cancer

Data Insights

Rituximab biosimilar by Shanghai Henlius Biotech for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Splenic Marginal Zone B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Rituximab Biosimilar in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Rectal Cancer: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Rectal Cancer. According to...

Data Insights

Serplulimab by Shanghai Henlius Biotech for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Serplulimab is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....

Data Insights

Serplulimab by Shanghai Henlius Biotech for Gastric Cancer: Likelihood of Approval

Serplulimab is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Gastric Cancer. According to GlobalData,...

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Nasopharyngeal Cancer: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Nasopharyngeal Cancer. According to...

Data Insights

Cetuximab biobetter by Shanghai Henlius Biotech for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Cetuximab biobetter is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Squamous Non-Small Cell Lung...

Data Insights

Rituximab biosimilar by Shanghai Henlius Biotech for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Rituximab biosimilar is under clinical development by Shanghai Henlius Biotech and currently in Phase II for Splenic Marginal Zone B-Cell...